MEDICINES CO /DE
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | |
|---|---|---|---|---|---|---|
| Revenue | $7.8M | $17.5M | $143.2M | $294.5M | $1.3M | $5.1M |
| Operating income | −$191.4M | −$665.1M | −$222.1M | −$185.1M | −$28.1M | $21.9M |
| Net income | $29.1M | −$102.7M | −$119.1M | −$352.8M | −$32.2M | $15.5M |
| Total assets | $841.7M | $873.0M | $1.71B | $1.80B | $1.89B | $1.74B |
| Total liabilities | $864.0M | $848.1M | $1.05B | $1.05B | $965.6M | $849.1M |
| Equity | −$22.3M | $24.9M | $652.5M | $732.2M | $920.6M | $892.5M |
| EPS (diluted) | $0.40 | $-1.45 | $-1.63 | $-5.28 | $-0.49 | $0.25 |
| Shares out. | 73.3M | 71.4M | 69.6M | 65.6M | 64.7M | 54.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2018- Operating margin
- −2463.1%
- Net margin
- 375.1%
- Return on equity
- −130.9%
- Return on assets
- 3.5%
- Return on capital (ROCE)
- −24.4%
- Liabilities / assets
- 102.6%
- Debt / equity
- —
- Book value / share
- $-0.30
- Revenue growth (YoY)
- −55.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2018- Altman Z″ (distress)
- -5.06distress
- Accruals / assets
- 34.6%high accruals
- Beneish M-Score
- -1.96normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 5 warning● 0 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- High accruals — earnings-quality risk
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Wijngaard PeterOfficer — Chief Development Officer | Jan 6, 2020 | D | 107,546 | — |
| Visioli ChristopherOfficer — Chief Financial Officer | Jan 6, 2020 | D | 68,843 | — |
| Timney MarkOfficer — Chief Executive Officer | Jan 6, 2020 | D | 185,415 | — |
| Schlesinger Sarah J.Director | Jan 6, 2020 | D | 7,429 | — |
| Rodin Stephen MOfficer — EVP and General Counsel | Jan 6, 2020 | D | 84,782 | — |
| Panayiotopoulos ParisDirector | Jan 6, 2020 | D | 13,881 | — |
| Meanwell CliveOfficer — Chief Innovation Officer | Jan 6, 2020 | D | 480,340 | — |
| Kelly John C.Director | Jan 6, 2020 | D | 32,148 | — |
| Germano Geno JDirector | Jan 6, 2020 | D | 7,429 | — |
| Denner Alexander JDirector | Jan 6, 2020 | D | 85,813 | — |
| Wijngaard PeterOfficer — Chief Development Officer | Dec 27, 2019 | Option exercise | 50,189 | $52.70 |
| Visioli ChristopherOfficer — Chief Financial Officer | Dec 27, 2019 | Option exercise | 6,000 | $17.45 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard noticeJan 6, 2020
- Entered a material agreement · Completed an acquisition or disposition · Debt acceleration / triggering event · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventJan 6, 2020
- Entered a material agreement · Regulation FD disclosureNov 25, 2019
- Results of operationsOct 30, 2019
- Results of operationsJul 24, 2019
- Regulation FD disclosure · Other material eventJun 28, 2019
- Shareholder voteJun 5, 2019
- Results of operationsApr 25, 2019
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 14, 2020
- SC 13G/ASCHEDULE 13G/AFeb 12, 2020
- SC 13G/ASCHEDULE 13G/AFeb 12, 2020
- SC 13G/AFeb 10, 2020
- SC 13G/AJan 28, 2020
- 15-12GJan 16, 2020
- EFFECTJan 9, 2020
- EFFECTJan 9, 2020
- EFFECTJan 9, 2020
- SC 13D/ASCHEDULE 13D (AMENDMENT NO. 1)Jan 7, 2020
- SC 13G/AWESTFIELD CAPITAL MANAGEMENT COMPANY, L.P.Jan 7, 2020
- 4OWNERSHIP DOCUMENTJan 6, 2020
- 4OWNERSHIP DOCUMENTJan 6, 2020
- 4OWNERSHIP DOCUMENTJan 6, 2020
- 4OWNERSHIP DOCUMENTJan 6, 2020
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.